Cornelia Tillack
Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD
Seiderer J, Lohse P, Müller-Myhsok B, Ochsenkühn T, Göke B, Konrad A, Schmechel S, Jürgens M, Pfennig S, Tillack C, Stallhofer J, Glas J, Diegelmann J, Elben I, Brand S. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis 2008; 14:437-45.
Apr 1, 2008Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD
Apr 1, 2008Inflamm Bowel Dis 2008; 14:437-45
Seiderer Julia, Lohse Peter, Müller-Myhsok Bertram, Ochsenkühn Thomas, Göke Burkhard, Konrad Astrid, Schmechel Silke, Jürgens Matthias, Pfennig Simone, Tillack Cornelia, Stallhofer Johannes, Glas Jürgen, Diegelmann Julia, Elben Ira, Brand Stephan
Genotype-phenotype analysis of the CXCL16 p.Ala181Val polymorphism in inflammatory bowel disease
Seiderer J, Reinecker H, Lohse P, Ochsenkühn T, Göke B, Müller-Myhsok B, Jürgens M, Pfennig S, Niess J, Glas J, Tillack C, Leistner D, Dambacher J, Brand S. Genotype-phenotype analysis of the CXCL16 p.Ala181Val polymorphism in inflammatory bowel disease. Clin Immunol 2008; 127:49-55.
Jan 11, 2008Genotype-phenotype analysis of the CXCL16 p.Ala181Val polymorphism in inflammatory bowel disease
Jan 11, 2008Clin Immunol 2008; 127:49-55
Seiderer Julia, Reinecker Hans-Christian, Lohse Peter, Ochsenkühn Thomas, Göke Burkhard, Müller-Myhsok Bertram, Jürgens Matthias, Pfennig Simone, Niess Jan-Hendrik, Glas Jürgen, Tillack Cornelia, Leistner Dorothea, Dambacher Julia, Brand Stephan
Macrophage migration inhibitory factor (MIF) -173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease
Dambacher J, Lohse P, Ochsenkühn T, Göke B, Diebold J, Otte J, Tillack C, Konrad A, Hofbauer K, Pfennig S, Schnitzler F, Sisic Z, Seiderer J, Staudinger T, Brand S. Macrophage migration inhibitory factor (MIF) -173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease. Inflamm Bowel Dis 2007; 13:71-82.
Jan 1, 2007Macrophage migration inhibitory factor (MIF) -173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease
Jan 1, 2007Inflamm Bowel Dis 2007; 13:71-82
Dambacher Julia, Lohse Peter, Ochsenkühn Thomas, Göke Burkhard, Diebold Joachim, Otte Jan-Michel, Tillack Cornelia, Konrad Astrid, Hofbauer Katrin, Pfennig Simone, Schnitzler Fabian, Sisic Zeljka, Seiderer Julia, Staudinger Tanja, Brand Stephan
Homozygosity for the CARD15 frameshift mutation 1007fs is predictive of early onset of Crohn's disease with ileal stenosis, entero-enteral fistulas, and frequent need for surgical intervention with high risk of re-stenosis
Seiderer J, Lohse P, Göke B, Sackmann M, Tillack C, Dambacher J, Hofbauer K, Herrmann K, Pfennig S, Staudinger T, Brand S, Schnitzler F, Ochsenkühn T. Homozygosity for the CARD15 frameshift mutation 1007fs is predictive of early onset of Crohn's disease with ileal stenosis, entero-enteral fistulas, and frequent need for surgical intervention with high risk of re-stenosis. Scand J Gastroenterol 2006; 41:1421-32.
Dec 1, 2006Homozygosity for the CARD15 frameshift mutation 1007fs is predictive of early onset of Crohn's disease with ileal stenosis, entero-enteral fistulas, and frequent need for surgical intervention with high risk of re-stenosis
Dec 1, 2006Scand J Gastroenterol 2006; 41:1421-32
Seiderer Julia, Lohse Peter, Göke Burkhard, Sackmann Michael, Tillack Cornelia, Dambacher Julia, Hofbauer Katrin, Herrmann Karin, Pfennig Simone, Staudinger Tanja, Brand Stephan, Schnitzler Fabian, Ochsenkühn Thomas
Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy
Seiderer J, Zech C, Diebold J, Schoenberg S, Brand S, Tillack C, Göke B, Ochsenkühn T. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. Eur J Gastroenterol Hepatol 2006; 18:553-5.
May 1, 2006Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy
May 1, 2006Eur J Gastroenterol Hepatol 2006; 18:553-5
Seiderer Julia, Zech Christoph J, Diebold Joachim, Schoenberg Stefan O, Brand Stephan, Tillack Cornelia, Göke Burkhard, Ochsenkühn Thomas
Eight novel CARD15 variants detected by DNA sequence analysis of the CARD15 gene in 111 patients with inflammatory bowel disease
Schnitzler F, Ochsenkühn T, Göke B, Tillack C, Seiderer J, Hofbauer K, Pfennig S, Staudinger T, Brand S, Lohse P. Eight novel CARD15 variants detected by DNA sequence analysis of the CARD15 gene in 111 patients with inflammatory bowel disease. Immunogenetics 2006; 58:99-106.
Feb 17, 2006Eight novel CARD15 variants detected by DNA sequence analysis of the CARD15 gene in 111 patients with inflammatory bowel disease
Feb 17, 2006Immunogenetics 2006; 58:99-106
Schnitzler Fabian, Ochsenkühn Thomas, Göke Burkhard, Tillack Cornelia, Seiderer Julia, Hofbauer Katrin, Pfennig Simone, Staudinger Tanja, Brand Stephan, Lohse Peter
Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease Phenotype
Brand S, Ochsenkühn T, Göke B, Konrad A, Tillack C, Seiderer J, Pfennig S, Staudinger T, Schnitzler F, Dambacher J, Hofbauer K, Lohse P. Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease Phenotype. Am J Gastroenterol 2006; 101:99-106.
Jan 1, 2006Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease Phenotype
Jan 1, 2006Am J Gastroenterol 2006; 101:99-106
Brand Stephan, Ochsenkühn Thomas, Göke Burkhard, Konrad Astrid, Tillack Cornelia, Seiderer Julia, Pfennig Simone, Staudinger Tanja, Schnitzler Fabian, Dambacher Julia, Hofbauer Katrin, Lohse Peter
The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease
Brand S, Lohse P, Göke B, Crispin A, Konrad A, Tillack C, Seiderer J, Dambacher J, Hofbauer K, Pfennig S, Schnitzler F, Staudinger T, Ochsenkühn T. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis 2005; 11:645-52.
Jul 1, 2005The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease
Jul 1, 2005Inflamm Bowel Dis 2005; 11:645-52
Brand Stephan, Lohse Peter, Göke Burkhard, Crispin Alexander, Konrad Astrid, Tillack Cornelia, Seiderer Julia, Dambacher Julia, Hofbauer Katrin, Pfennig Simone, Schnitzler Fabian, Staudinger Tanja, Ochsenkühn Thomas